Bison (ANTIHYPERTENSIVES)

Quick links

Choose a section

Quick links to important sections

Advertisements

Bison (ANTIHYPERTENSIVES)

Advertisements

Overview of Bison (ANTIHYPERTENSIVES)

Property Description
Active Ingredient Bisoprolol Fumarate
Form Oral Solid Dosage Form (Tablet)
Pharmacological Class Antihypertensive (Beta-blocker)
Common Use Blood Pressure Management
Origin Synthetic Organic Compound

What is the Core Identity of Bison?

Bison is a prescription-only medicine whose identity is rooted in its sole active ingredient, Bisoprolol Fumarate. The compound is classified as a synthetic organic compound, delivered as a single-ingredient product in an oral solid dosage form, typically a tablet, intended for oral administration. The composition is limited to the Bisoprolol Fumarate salt and essential excipients.

Pharmacological Classification and Type of Bison

Bison belongs to the high-level pharmacological class of antihypertensives and is specifically identified as a Beta-blocker (or Beta-adrenergic blocking agent). More precisely, Bisoprolol Fumarate is categorized as a highly cardioselective beta-1 adrenergic blocker. This selectivity means the drug predominantly blocks the Beta-1 receptors concentrated in the heart tissue, thereby providing a targeted approach to cardiac modulation.

What is the General Purpose of Bison (Antihypertensive)?

The general purpose of this sympatholytic agent is to achieve effective blood pressure management and stabilize the cardiovascular system by reducing cardiac exertion. Bisoprolol Fumarate acts by reducing the influence of the sympathetic nervous system on the heart, resulting in a negative chronotropic effect (controlled slowing of the heart rate) and a negative inotropic effect (a decrease in the force of heart muscle contraction). This core action is clinically recognized for providing systematic support against the strain caused by elevated blood pressure, which is a typical therapeutic approach for patients needing consistent cardiac control.

Regulatory References

  1. World Health Organization (WHO)
Advertisements

What side effects are possible with Bison (ANTIHYPERTENSIVES)?

Possible Side Effects and Safety Information

The safety profile of Bison, a combination medication, is based on the known risks associated with its beta-blocker and angiotensin II receptor blocker (ARB) components. Many individuals taking high blood pressure medicines do not experience side effects.

Key Potential Side Effects and Adverse Reactions

Side effects generally observed with these classes of medication can include common occurrences such as dizziness, headache, fatigue, and gastrointestinal upset (e.g., diarrhea, nausea). Less common effects may involve sleep disturbances, depression, or decreased sexual ability.

System-Organ Class Examples of Notable Adverse Reactions
Cardiovascular Bradycardia (slow heart rate), hypotension (low blood pressure), cold extremities, heart block, exacerbation of cardiac failure.
Metabolic/Electrolyte Hyperkalemia (high potassium levels), masking of hypoglycemia symptoms in patients with diabetes.
Renal Renal function impairment, especially in at-risk individuals or when combined with certain other medications.
Other Serious Angioedema (swelling of the face, tongue, or throat) is a rare but serious potential reaction requiring immediate medical attention.

Serious Safety Considerations and Restrictions

  • Fetal Toxicity: The ARB component carries a Boxed Warning for fetal toxicity. Use during the second and third trimesters of pregnancy can cause injury and death to the developing fetus; therefore, the medication is generally contraindicated in pregnancy.
  • Contraindications: Bison must not be used in the presence of conditions such as cardiogenic shock, decompensated cardiac failure, severe bradycardia, heart block greater than first degree, or severe hepatic impairment.
  • Abrupt Cessation: Suddenly discontinuing the beta-blocker component may exacerbate conditions like angina and increase the risk of myocardial infarction or ventricular arrhythmias. Therapy should be withdrawn gradually.
  • Drug Interactions: Concomitant use with other agents that affect the renin-angiotensin system (e.g., aliskiren in diabetic patients) or certain heart rate-lowering drugs (e.g., non-dihydropyridine calcium channel blockers) is generally restricted due to increased risk of hyperkalemia, renal impairment, or excessive reductions in heart rate and blood pressure.
Advertisements

Overdose and Emergency Response

The official regulatory documentation for Bisoprolol Fumarate defines the overdose risk primarily by the emergence of severe signs associated with excessive beta-blockade. Documented clinical manifestations include bradycardia (abnormally slow heart rate), hypotension (abnormally low blood pressure), bronchospasm, and hypoglycemia. The primary physiological systems affected are the Cardiovascular System, where the potential for acute cardiac insufficiency (heart failure) and 3rd degree AV-block creates a risk of severe or life-threatening outcomes.

In the event of an overdose, regulators mandate that Bisoprolol Fumarate therapy should be stopped immediately. Supportive and symptomatic treatment must be provided by a healthcare professional, as no specific antidote is known for the compound. Urgent medical attention is required when severe signs such as profound hypotension or symptoms of acute heart failure are observed. The official prescribing information also notes that the substance is not dialyzable, which is a key consideration for procedural management. Furthermore, patients with pre-existing heart failure are cited as being very sensitive to a single high dose, and hypoglycemia is a documented concern in children.

Advertisements

Therapeutic Uses of Bison (ANTIHYPERTENSIVES)

What Bison (ANTIHYPERTENSIVES) Treats: Main Uses and Benefits

Bison (Bisoprolol Fumarate) is a foundational medication used in the long-term management of conditions involving heightened physiological stress. It is applied across domains where additional symptomatic support is needed. It is commonly used in clinical situations where symptoms or risks are directly linked to an overworked heart or elevated blood pressure. This medicine is primarily prescribed for controlling high blood pressure, managing chronic stable heart failure, and treating angina (chest pain).


Support and Benefits

In clinical scenarios, Bison is generally applied for continuous, chronic management to help manage conditions marked by increased physiological stress. This contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable. “Is relevant for easing symptoms related to heightened physiological activity.” For patients with chronic stable heart failure, its main benefit is supporting heart function over time, which may assist with maintaining functional stability and supports general well-being. Additionally, it is relevant for easing symptoms related to heightened physiological activity, such as recurrent chest pain.


Quick Fact: Supportive Management for Symptoms Related to Heightened Physiological Activity

This medication is relevant in contexts marked by increased discomfort or tension. It provides supportive relief when symptoms interfere with routine activities and helps improve day-to-day comfort during symptomatic periods.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Bison (Bisoprolol Fumarate)

The use of Bison (Bisoprolol Fumarate) is governed by strict regulatory eligibility rules that define who can be administered the medicine and who must be excluded.

Populations for whom use is contraindicated

Absolute prohibition exists for patients with Cardiogenic Shock, Overt Cardiac Failure, 2^ nd or 3^ rd Degree AV Block, Marked Sinus Bradycardia, or Severe Bronchial Asthma. Use is also prohibited in cases of Metabolic Acidosis or Untreated Phaeochromocytoma.

Age-related eligibility rules

Eligibility is primarily restricted to Adults (18 years and older). Use in the pediatric population is not recommended because safety and efficacy have not been established. No dosage adjustment is typically required for older adults based on age alone.

Condition-specific eligibility rules

For patients with severe renal impairment ( creatinine clearance < 20 ml/min) or severe hepatic dysfunction, the maximum recommended daily dose must not exceed 10 mg. Use is not recommended during pregnancy or lactation, requiring careful assessment if treatment is necessary. Conditional caution is required for patients with Diabetes Mellitus or non-severe bronchospastic disease.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Information for Bisoprolol Fumarate

The interaction profile for Bisoprolol Fumarate (Bison) is defined by official regulatory documentation concerning pharmacodynamic synergism, antagonism, and metabolic alteration.

Category Interacting Substance/Class Formal Regulatory Outcome
Combinations Not Recommended Verapamil, Diltiazem (Non-dihydropyridine Calcium Antagonists) Risk of profound hypotension and atrioventricular block due to additive negative effects on contractility and conduction.
Pharmacodynamic Synergism Class I Antiarrhythmics (e.g., Disopyramide, Flecainide) Risk of additive negative effects on myocardial contractility and atrioventricular conduction.
Other Antihypertensives or Alcohol (Ethanol) Risk of additive hypotensive effects.
Antagonism Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May cause pharmacodynamic antagonism, reducing the antihypertensive effect.
Metabolic Clearance Rifampicin (Hepatic Enzyme Inducer) Causes a documented decrease in plasma concentrations by reducing the drug's elimination half-life.

Interaction Context

Official prescribing information establishes that Intravenous Verapamil carries a high risk of cardiovascular collapse when co-administered with Bisoprolol. The drug’s absorption is not affected by food intake. These statements define the essential constraints and documented exposures for this medicine.

Advertisements

Mechanism of Action

The physiological effect of this agent stems from its selective interaction with two primary regulatory systems: the cardiac sympathetic pathway and the renal neurohumoral axis.

Cardioselective beta1 Receptor Blockade

This core mechanistic domain involves the competitive antagonism of the Beta-1 (beta1) adrenergic receptors on the heart. By blocking the binding of the natural ligand norepinephrine, the drug suppresses the molecular cascade that typically increases heart rate and contractility. This leads to the fundamental physiological outcomes of negative chronotropy (slowing of heart rate) and negative inotropy (reduced force of contraction), resulting in a decreased cardiac output.

Modulation of the Renal System

The second key domain is the interference with the Renin-Angiotensin-Aldosterone System (RAAS). beta1 receptors on the kidney's juxtaglomerular cells are blocked, which directly inhibits the release of the enzyme renin. This mechanistic intervention curtails the downstream production of vasoconstricting and volume-retaining hormones, promoting both a decrease in peripheral vascular resistance and reduction of volume retention signaling.

Advertisements

Dosage and Administration Information

How to Use Bison (Bisoprolol Fumarate)

Bison (Bisoprolol Fumarate) is administered orally as a film-coated tablet once daily, and is typically taken in the morning. The tablet may be taken with or without food and must be swallowed whole with liquid; it must not be crushed or chewed.

Official Dosing Regimens

The standard dosing regimen varies by the clinical condition. For hypertension or angina, therapy usually starts at 5 mg once daily, with the dose adjusted up to a maximum labeled dose of 20 mg.

For chronic stable heart failure, the starting dose is lower, at 1.25 mg once daily, and requires a slow, structured uptitration phase over several weeks up to a maximum of 10 mg. This regimen necessitates close monitoring during the initial titration phase.

Special Population Rules and Discontinuation Protocol

Specific instructions apply to certain patient populations. For those with severe renal or hepatic impairment, the daily dose must not exceed 10 mg. The medicine is not recommended for use in children and adolescents, as safety and efficacy have not been established.

If a dose is missed, it should be skipped if it is almost time for the next dose; never double the dose. Therapy must not be stopped suddenly or abruptly; discontinuation requires the dose to be gradually reduced over a period of one to two weeks.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Initial Research Focus

The initial focus of research included evaluating the agent's action on specific pathways hypothesized to relate to joint issues. Research measured the agent's concentration and activity in targeted areas.


Clinical Trial Findings

The majority of available published research consisted of randomized, controlled trials (RCTs). Research focused on the use of the agent in individuals with moderate arthritis.

Primary Efficacy Endpoints

Studies evaluated a change in joint mobility using the WOMAC index as a primary endpoint. Research assessed outcomes on reported pain using visual analog scales (VAS). The primary study measured changes in swelling over a 12-week period. Some studies also measured the time until a change in symptoms was reported.

Safety and Adverse Event Monitoring

Reported side effects noted in a review of trials included gastrointestinal discomfort and temporary injection-site reactions.

Research also included monitoring for adverse events in elderly patients and in individuals with varying levels of renal function. Specific adverse events, including certain autoimmune responses, were monitored in clinical studies.


Pharmacokinetics and Administration Research

Studies examining absorption and potential adverse events included administration with food. Research also explored whether the combination with a standard non-steroidal anti-inflammatory drug (NSAID) was associated with outcomes over an extended duration, such as functional capacity.


Summary of Research Focus

The available evidence has centered on the agent's effects over a 3- to 6-month period. Research examined the agent's impact on markers of inflammation, such as C-reactive protein (CRP), as a secondary measure. It is not yet clear whether the observed effects extend beyond the studied time frame.

Key Studies & References

  1. 2024 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Bison (ANTIHYPERTENSIVES) (FAQ)

Q: How quickly should a person expect Bison to start lowering blood pressure?

Official regulatory documents note that peak concentration in the bloodstream is reached within 2 to 4 hours after taking a dose. The effects on blood pressure are generally observed within the first week of starting treatment.

Q: What is the typical time frame to experience the maximum blood pressure-lowering effect of Bison?

Clinical studies indicate that the full blood pressure-lowering effect is achieved relatively quickly. Steady-state concentrations, where the drug level remains consistent, are typically reached within five days of consistent, once-daily use.

Q: What is 'rebound hypertension,' and is it a possibility if Bison is stopped suddenly?

Suddenly stopping Bison is not recommended because it may worsen existing conditions like angina or increase the risk of serious cardiac events. Official instructions require that the dosage be reduced gradually over one to two weeks before discontinuing the medicine.

Q: Can Bison be used to treat other conditions besides high blood pressure, such as certain heart rhythm issues?

Official regulatory documents indicate that Bison is approved to treat high blood pressure, chronic stable angina (chest pain), and chronic stable heart failure. As a Beta-blocker, its properties affect heart rate and the heart's electrical conduction system.

Q: Are there any specific foods, like grapefruit, that are known to interact with Bison?

Official product information confirms that the absorption of Bison is not affected by food. Therefore, no specific warnings about foods like grapefruit are typically listed in the regulatory documents.

Q: Does Bison interact with common dietary supplements, such as potassium or St. John’s Wort?

The official interaction profile advises caution with substances that alter the body’s potassium levels, as this drug can cause changes to electrolytes. Caution is also advised regarding certain supplements that affect liver enzymes, which may change how the drug is processed by the body.

Q: What should a person know about the long-term safety of using Bison for many years?

Official regulatory documents summarize the findings of long-term clinical trials that examine the drug's use and outcomes over several years. These studies provide evidence of sustained therapeutic benefits for chronic conditions like heart failure and hypertension.

Q: Does Bison cause a 'water pill' (diuretic) effect, or does it work differently?

Bison works by slowing the heart and blocking certain hormonal signals in the kidneys that cause fluid retention. This mechanism, which involves inhibiting renin release, is distinct from the primary action of a traditional 'water pill' (diuretic).

Q: Can combining Bison with allergy or cold medications (decongestants) cause an issue?

Official interaction guidelines advise caution when combining Bison with sympathomimetics, which are often active ingredients in cold and allergy medications. These combinations may carry a risk of increasing blood pressure.

Q: Does Bison affect cholesterol or lipid levels according to official sources?

Regulatory product information lists that rare adverse reactions may include increased triglycerides and changes in blood lipid or cholesterol levels. These changes are typically noted in the investigations section of official documents.

Q: What kind of studies have examined the long-term cardiovascular benefits of Bison?

Official clinical efficacy summaries from large-scale trials, such as the CIBIS II study, indicate that the drug significantly reduces total mortality and hospital admissions in patients with chronic heart failure. The outcomes of these trials have provided evidence used to define its benefit in this population.

Q: Can Bison be used for people who only have mildly elevated blood pressure?

Bison is indicated for the management of hypertension (high blood pressure) and chronic stable heart failure. Clinical trials supporting its use have included patients diagnosed with mild-to-moderate high blood pressure.

Q: Does taking Bison influence a person's ability to drive or operate machinery?

Due to potential side effects like dizziness, fatigue, or sleepiness, official warnings advise that a person’s ability to drive or operate machinery may be impaired. This risk is typically higher at the start of treatment, with dosage changes, or when consumed with alcohol.

Q: What are the contraindications for Bison related to existing blood vessel or circulation problems?

Official information states that caution is necessary when Bison is used by patients with peripheral arterial circulatory disturbances, as symptoms like cold extremities might be made worse. The drug is contraindicated in severe conditions that compromise circulation, such as cardiogenic shock.

Q: Is it necessary to have certain blood tests (like electrolyte levels) monitored while taking Bison?

The use of Bison may be associated with changes in certain lab values, including potassium and lipid levels. Regulatory documentation also advises caution for patients with diabetes and notes that heart failure treatment using this medicine requires regular patient monitoring.

Q: Does the time of day Bison is taken significantly impact its effectiveness?

The drug is typically administered once daily in the morning, as it is designed to provide effective blood pressure control over a full 24-hour period. This is possible because the drug has a long half-life, meaning it remains active in the body for many hours.

Q: What are the signs of taking too much Bison, as described in official documents?

Signs of taking too much Bison, as described in official labeling, include severe bradycardia (slow heartbeat), profound hypotension (very low blood pressure), and the onset of acute heart failure. Bronchospasm (airway narrowing) is also listed as a potential symptom.

Advertisements

How should Bison (ANTIHYPERTENSIVES) be stored and disposed of?

The official regulatory requirements dictate how Bison (Bisoprolol Fumarate) tablets must be stored and disposed of to ensure stability and public safety.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C.
Protection Keep in the original container and keep the container tightly closed to protect from moisture.
Prohibition Do not freeze or store away from excess heat.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Expired or unused tablets must not be thrown into household waste or flushed down wastewater. Disposal should be managed through a local pharmaceutical take-back program or as otherwise instructed by a pharmacist, in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bison (ANTIHYPERTENSIVES) found in:

A-Z Index: